Stryker (NYSE:SYK) Raised to “Strong-Buy” at BMO Capital Markets

Stryker (NYSE:SYK) was upgraded by research analysts at BMO Capital Markets to a “strong-buy” rating in a report issued on Wednesday,Zacks.com reports.

A number of other analysts have also recently issued reports on the company. Sanford C. Bernstein set a $410.00 target price on Stryker in a report on Friday, May 1st. Robert W. Baird set a $385.00 price target on shares of Stryker in a research report on Friday, May 1st. JPMorgan Chase & Co. decreased their price objective on shares of Stryker from $445.00 to $400.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. UBS Group dropped their price objective on shares of Stryker from $400.00 to $380.00 and set a “neutral” rating for the company in a research report on Tuesday, March 17th. Finally, Evercore set a $350.00 target price on shares of Stryker in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $392.87.

Stryker Trading Up 0.0%

SYK stock opened at $326.87 on Wednesday. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. The company has a market cap of $125.31 billion, a price-to-earnings ratio of 37.83, a PEG ratio of 2.09 and a beta of 0.77. The business has a fifty day simple moving average of $309.82 and a 200-day simple moving average of $338.02. Stryker has a 52 week low of $281.00 and a 52 week high of $404.87.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). The firm had revenue of $6.02 billion for the quarter, compared to analysts’ expectations of $6.34 billion. Stryker had a net margin of 13.20% and a return on equity of 23.42%. Stryker’s revenue was up 2.6% on a year-over-year basis. During the same period last year, the firm posted $2.84 EPS. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, equities research analysts expect that Stryker will post 14.98 EPS for the current year.

Insider Buying and Selling

In related news, VP M Kathryn Fink sold 5,220 shares of the stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $283.85, for a total value of $1,481,697.00. Following the completion of the transaction, the vice president owned 13,137 shares of the company’s stock, valued at approximately $3,728,937.45. This represents a 28.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director directly owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. This represents a 13.87% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 323,264 shares of company stock worth $100,659,489. 4.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Stryker

A number of hedge funds have recently made changes to their positions in the stock. VanderPol Investments L.L.C. raised its holdings in Stryker by 1.4% in the fourth quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock valued at $732,000 after acquiring an additional 28 shares in the last quarter. KCM Investment Advisors LLC grew its holdings in Stryker by 1.5% during the 4th quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock worth $653,000 after acquiring an additional 28 shares in the last quarter. Rossby Financial LCC increased its position in shares of Stryker by 6.6% in the 4th quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock worth $159,000 after purchasing an additional 28 shares during the last quarter. Tcfg Wealth Management LLC increased its position in shares of Stryker by 2.7% in the 3rd quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock worth $403,000 after purchasing an additional 29 shares during the last quarter. Finally, Mechanics Financial Corp raised its stake in shares of Stryker by 1.2% in the 4th quarter. Mechanics Financial Corp now owns 2,458 shares of the medical technology company’s stock valued at $864,000 after purchasing an additional 30 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.